ClinicalTrials.gg
CompletedNCT02743949Updated Feb 18, 2020Results posted

Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI)

A Phase 2 interventional study of Vonoprazan and Esomeprazole in Gastroesophageal Reflux, sponsored by Takeda. Completed at 39 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-18.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
256
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies testing esomeprazole in Gastroesophageal Reflux — 1 open to participants now, 1 under way, none of them phase 3. Esomeprazole · Gastroesophageal Reflux.

Enrollment
24th of 66
256 · median 125
Started
2016
the only one that year
Phase 2
5 of 67
none open now
Registered
57th of 67
by date

Among the 67 studies testing esomeprazole in Gastroesophageal Reflux, this one is the 24th largest by enrollment of the 66 interventional ones that give a count, is the only one that started in 2016, is one of 5 in phase 2, and was the 57th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

1 of the 67 studies testing esomeprazole in Gastroesophageal Reflux is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About esomeprazole

Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing esomeprazole in Gastroesophageal Reflux, or all of them as a file.
02

Study summary

The purpose of this study is to determine the effect of vonoprazan compared to esomeprazole for preventing heartburn symptoms over a 4-week treatment period in participants who have a partial response to treatment with esomeprazole.

Read the detailed description

The drug being tested in this study is called vonoprazan. Vonoprazan is being tested to treat people who have symptomatic gastroesophageal reflux disease (GERD) with a partial response to treatment with a high dose of esomeprazole. This study will look at improvement in heartburn symptoms in participants who take vonoprazan compared to esomeprazole.

The study will enroll approximately 213 patients. All participants will receive esomeprazole or esomeprazole placebo-matching capsules (this is a capsule that looks like esomeprazole but has no active ingredient) during a 7-week run-in period. Participants will then be randomly assigned (by chance, like flipping a coin) to one of the three treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):

  • Esomeprazole 40 mg
  • Vonoprazan 20 mg
  • Vonoprazan 40 mg

All participants will be asked to take one capsule at the same time each day throughout the study. All participants will be asked to record heartburn symptoms in a diary every morning upon waking and every evening before going to sleep.

This multi-center trial will be conducted in Europe. The overall time to participate in this study is 12 weeks. Participants will make multiple visits to the clinic, and will be contacted by telephone 1 week after the last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Gastroesophageal Reflux

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedures.
  3. Is a man or a woman and ≥18 years of age, at the time of the Screening visit.
  4. Has a documented history of symptoms of both heartburn (burning pain) and acid regurgitation prior to entry into the study.
  5. The subject has a medical history of ≥ 8 weeks of persistent heartburn symptoms in the presence of regurgitation symptoms (persistent heartburn symptoms defined as heartburn symptoms on ≥ 2 days a week) that are troublesome despite appropriate and correctly performed treatment with a PPI at standard doses.
  6. Is ≥85% compliant at taking their Run-in medication and completing their e-Diary. Compliance for taking the Run-in medication is defined as the medication provided (esomeprazole and placebo) taken for 85% of the 6 weeks Run-in Period (or on 36 of 42 days of the Run-in Period).Compliance for the e-Diary is defined as the percentage of scheduled assessments that are completed based on 2 assessments per day (daytime and nighttime). For randomization, 85% compliance is required and is defined as 12 of 14 assessments completed over the 7-day period (Day -21 to Day-14) prior to the single blind Placebo Run-in Period.
  7. Has a partial response to a PPI defined as having heartburn on 2 to 5 days and regurgitation on at least one day of the last week (Week 4) of a 4 week PPI Run-In Period with esomeprazole 40 mg and an increase of at least 2 symptom days of heartburn in the last week of a 2 week Placebo Run-In Period (4 to 7 symptom days) and at least one symptom day with regurgitation compared with the last week of the PPI Run-In Period.
  8. A female participant of who is sexually active with a nonsterilized male partner agrees to use routinely adequate from signing of informed consent throughout the duration of the study and for 4 weeks after last dose of the study medication.

Exclusion criteria

Exclusion Criteria:

  1. Has received any compound within 30 days prior to the Screening Visit.
  2. Has received vonoprazan in a previous clinical study.
  3. Is an immediate family member, study site employee, is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling), or may have consented under duress.
  4. Has, in the judgment of the investigator, abnormal hematological parameters of , hematocrit, or erythrocytes at Screening.
  5. Has a history of erosive esophagitis of Los Angeles (LA) Classification Grade B severity or worse prior to screening or at Screening endoscopy.
  6. Has a history of or any coexisting diseases affecting the esophagus (eg, Barrett's esophagus, eosinophilic esophagitis, esophageal varices, scleroderma, viral or fungal infection, or esophageal stricture), history of radiation therapy or cryotherapy to the esophagus, caustic trauma, or physiochemical trauma such as sclerotherapy to the esophagus.
  7. Has "alarm features" in symptomatology, including odynophagia, severe dysphagia, bleeding, weight loss, anemia, and blood in stool, pointing to a possible malignant disease of the gastrointestinal (GI) tract. Participants displaying "alarm symptoms" in addition to the "typical" gastroesophageal reflux disease (GERD) symptoms may be included based on endoscopic exclusion of .
  8. Has current or historical chest pain due to cardiac diseases (eg, within one year).
  9. Has had surgical treatment for GERD (eg, cardiaplasty), dilation of an esophageal stricture (other than Schatzki ring) or gastric or duodenal surgery, except simple oversew of an ulcer or endoscopic polypectomy of benign polyps.
  10. Has active gastric or duodenal ulcers which have been confirmed by endoscopy within 30 days prior to Screening. Gastric or duodenal erosions are not exclusionary, unless considered severe and symptomatic by the investigator.
  11. Has had an acute upper gastrointestinal hemorrhage within 30 days prior to Screening.
  12. Has current or historical evidence of Zollinger-Ellison syndrome or other hypersecretory condition.
  13. Has current or historical evidence of eosinophilic esophagitis (evidence may be based on the following: missing response to acid suppressive therapy, the presence of eosinophilia in histological probes of the esophageal mucosa, a normal pH profile of the distal esophagus, symptoms of dysphagia and food impaction). The exclusion of participants based on a predominance of the "typical" eosinophilic esophagitis symptoms only (as above) is considered acceptable. However, in participants with a predominance of "typical" symptoms and co-existing significant dysphagia and food impaction, the syndrome should be excluded by endoscopy with .
  14. Has a documented history (within 6 months prior to screening) of functional dyspepsia (suggested by the presence of one or more of the following symptoms: epigastric pain, postprandial fullness or early satiety), or irritable bowel syndrome or other gastrointestinal diseases which are not acid-related, and therefore, are nonresponsive to gastric acid-blocking treatment.
  15. Has a documented history of familial adenomatous polyposis.
  16. Has known intolerance, or allergies to any PPI or their components (including lansoprazole, dexlansoprazole, omeprazole, rabeprazole, pantoprazole, or esomeprazole), any component of vonoprazan, or antacid(s) selected as rescue medication for this study.
  17. Has a history of alcohol abuse, illegal drug use, or drug addiction within the 12 months prior to Screening, or regularly consumes >21 units of alcohol (1 unit = 12 oz/300 mL beer, 1.5 oz/25 mL hard liquor/spirits, or 5 oz/100 mL wine) per week. Participants must have a negative drug screen at Screening.
  18. Has evidence of a serious uncontrolled concomitant disease including: clinically significant neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, systemic, or endocrine disease or other abnormality (other than the disease being studied), which may impact the ability of the participant to participate or potentially confound the study results.
  19. Has planned, or is likely to require, in-patient surgery during the course of the study.
  20. Has a history of cancer (except basal cell carcinoma of the skin) within 3 years prior to Screening.
  21. Is known to have acquired immunodeficiency syndrome or chronic hepatitis due to any etiology.
  22. Has abnormal laboratory values at Screening that suggest a clinically significant underlying disease or condition that may prevent the participant from completing the study.
  23. Has an (ALT), aspartate aminotransferase (AST) or T- level which exceeds (ULN) set by the testing laboratory at the Screening.
  24. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period.
  25. Is required to take excluded medications or it is anticipated that the participant will require treatment with at least 1 of the disallowed concomitant medications during the study.
  26. In the opinion of the investigator, is unable to comply with the requirements of the study or is unsuitable for any reason.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
256 participants (actual)

Study arms

  • Active comparator
    Esomeprazole 40 mg

    Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by esomeprazole 40 mg, over encapsulated tablets, orally, once daily for 4 weeks during the active treatment period.

    Drug: Vonoprazan · Drug: Esomeprazole · Drug: Esomeprazole Placebo

  • Experimental
    Vonoprazan 20 mg

    Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by vonoprazan 20 mg, over-encapsulated capsules, orally, once daily for 4 weeks during the treatment period.

    Drug: Vonoprazan · Drug: Esomeprazole · Drug: Esomeprazole Placebo

  • Experimental
    Vonoprazan 40 mg

    Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by vonoprazan 40 mg, over-encapsulated capsules, orally, once daily for 4 weeks during the active treatment period.

    Drug: Esomeprazole · Drug: Esomeprazole Placebo

Interventions

  • Vonoprazan over-encapsulated capsules

    Also known as: TAK-438

  • Esomeprazole over-encapsulated tablets

  • DrugEsomeprazole Placebo

    Esomeprazole placebo-matching capsules

06

What researchers measure

Primary outcomes

  1. Percentage of Heartburn-Free 24-Hour Periods (Day and Night) During 4 Weeks of Treatment

    Participants used the Reflux Symptom Questionnaire Electronic Diary (RESQ-eD) every morning upon waking and every evening before going to sleep to document the presence of daytime and nighttime heartburn and regurgitation. The percentage of heartburn-free (HBF) 24-hour periods was calculated for each participant using the following formula: (total 24-hour periods that are heartburn free / total 24-hour periods for which both a daytime and nighttime result is marked) x 100%.

    Time frame: 4 Weeks

Secondary outcomes

  1. Percentage of Participants With ≥1 Sustained Resolution of Heartburn During the 4-Week Treatment Period

    ≥1 sustained resolution of heartburn is defined as ≥7 consecutive days without both daytime and nighttime heartburn anytime during the 4-week treatment period. Daytime and nighttime heartburn were documented by all participants using the Reflux Symptom Questionnaire Electronic Diary (RESQ-eD).

    Time frame: 4 Weeks

07

Results

Posted Feb 18, 2020
Limitations and caveats
43 more participants enrolled due to lower screen failure rate in the 5 new sites and the long run in period limited predictability of enrolment in advance. Measures had been implemented maintaining scientific integrity and participant safety.

Participant flow

Participants took part in the study at 33 investigative sites in Belgium, Bulgaria, Czech Republic, Estonia, Poland and United Kingdom from 14 July 2016 to 12 October 2018.

Participant flow — Overall Study
MilestoneEsomeprazole 40 mgVonoprazan 20 mgVonoprazan 40 mg
Started868585
Completed828482
Not completed413
Withdrew: Adverse event002
Withdrew: Significant protocol deviation201
Withdrew: Voluntary withdrawal210

Outcome measures

PrimaryPercentage of Heartburn-Free 24-Hour Periods (Day and Night) During 4 Weeks of Treatment

Participants used the Reflux Symptom Questionnaire Electronic Diary (RESQ-eD) every morning upon waking and every evening before going to sleep to document the presence of daytime and nighttime heartburn and regurgitation. The percentage of heartburn-free (HBF) 24-hour periods was calculated for each participant using the following formula: (total 24-hour periods that are heartburn free / total 24-hour periods for which both a daytime and nighttime result is marked) x 100%.

Time frame:
4 Weeks
Reported as:
Mean · percentage of HBF 24-hour periods
Percentage of Heartburn-Free 24-Hour Periods (Day and Night) During 4 Weeks of Treatment
percentage of HBF 24-hour periodsEsomeprazole 40 mgVonoprazan 20 mgVonoprazan 40 mg
Percentage of Heartburn-Free 24-Hour Periods (Day and Night) During 4 Weeks of Treatment36.54 ± 35.57036.69 ± 33.42038.43 ± 34.793
Statistical analysis
  • Esomeprazole 40 mg vs Vonoprazan 20 mg · Wilcoxon rank-sum test · p = 0.7480 (P-values were obtained using a Pearson chi-square test for each Vonoprazan treatment compared with Esomeprazole.) · Wilcoxon-mann-whitney odds estimator: 1.0584 · 97.5% CI 0.7100 to 1.5778
  • Esomeprazole 40 mg vs Vonoprazan 40 mg · Wilcoxon rank-sum test · p = 0.5985 (P-values were obtained using a Pearson chi-square test for each Vonoprazan treatment compared with Esomeprazole.) · Wilcoxon-mann-whitney odds estimator: 1.0975 · 97.5% CI 0.7368 to 1.6349
SecondaryPercentage of Participants With ≥1 Sustained Resolution of Heartburn During the 4-Week Treatment Period

≥1 sustained resolution of heartburn is defined as ≥7 consecutive days without both daytime and nighttime heartburn anytime during the 4-week treatment period. Daytime and nighttime heartburn were documented by all participants using the Reflux Symptom Questionnaire Electronic Diary (RESQ-eD).

Time frame:
4 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants With ≥1 Sustained Resolution of Heartburn During the 4-Week Treatment Period
percentage of participantsEsomeprazole 40 mgVonoprazan 20 mgVonoprazan 40 mg
Percentage of Participants With ≥1 Sustained Resolution of Heartburn During the 4-Week Treatment Period32.630.631.8
Statistical analysis
  • Esomeprazole 40 mg vs Vonoprazan 20 mg · Pearson chi-square · p = 0.782 (P-values were obtained using a Pearson chi-square test for each Vonoprazan treatment compared with Esomeprazole.) · Miettinen-nurminen: 0.91 · 97.5% CI 0.44 to 1.91
  • Esomeprazole 40 mg vs Vonoprazan 40 mg · Pearson chi-square · p = 0.912 (P-values were obtained using a Pearson chi-square test for each Vonoprazan treatment compared with Esomeprazole.) · Miettinen-nurminen: 0.96 · 97.5% CI 0.46 to 2.01

Adverse events

Collected over Up to 5 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Esomeprazole 40 mg0/86 (0%)1/86 (1.2%)1/86 (1.2%)
Vonoprazan 20 mg0/85 (0%)0/85 (0%)0/85 (0%)
Vonoprazan 40 mg0/85 (0%)0/85 (0%)6/85 (7.1%)
Most frequent serious events
Most frequent serious events
EventEsomeprazole 40 mgVonoprazan 20 mgVonoprazan 40 mg
Ischaemic strokeNervous system disorders1/860/850/85
Most frequent other events
Most frequent other events
EventEsomeprazole 40 mgVonoprazan 20 mgVonoprazan 40 mg
HypothyroidismEndocrine disorders0/860/853/85
FlatulenceGastrointestinal disorders1/860/852/85
Urinary tract infectionInfections and infestations0/860/852/85

Baseline characteristics

The randomized set included all participants who were randomized into the study, regardless of whether they received any dose of the study drug.

Age, Continuous
Age, Continuous(years)Esomeprazole 40 mgVonoprazan 20 mgVonoprazan 40 mgTotal
Mean53.9 ± 13.9452.0 ± 14.6751.8 ± 14.0952.6 ± 14.21
Sex: Female, Male
Sex: Female, Male(Participants)Esomeprazole 40 mgVonoprazan 20 mgVonoprazan 40 mgTotal
Female485351152
Male383234104
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Esomeprazole 40 mgVonoprazan 20 mgVonoprazan 40 mgTotal
American Indian or Alaska Native0000
Asian0011
Native Hawaiian or Other Pacific Islander0011
Black or African American0101
White868483253
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)Esomeprazole 40 mgVonoprazan 20 mgVonoprazan 40 mgTotal
Belgium0101
Bulgaria615561177
Czech Republic14161040
Estonia25411
Poland87722
United Kingdom1135
Smoking Status
Smoking Status(Participants)Esomeprazole 40 mgVonoprazan 20 mgVonoprazan 40 mgTotal
Participant has never smoked505353156
Participant is a current smoker21232266
Participant is an ex-smoker1591034
Alcohol Classification
Alcohol Classification(Participants)Esomeprazole 40 mgVonoprazan 20 mgVonoprazan 40 mgTotal
Participant has never drunk574954160
Participant is a current drinker27333090
Participant is an ex-drinker2316
Alcohol Use
Alcohol Use(Participants)Esomeprazole 40 mgVonoprazan 20 mgVonoprazan 40 mgTotal
Less than 21 units of alcohol per week27333090
Missing595255166
Caffeine Consumption
Caffeine Consumption(Participants)Esomeprazole 40 mgVonoprazan 20 mgVonoprazan 40 mgTotal
Yes606768195
No26181761

9 further baseline measures are reported on the registry.

08

Study locations

39 sites
  • Medif
    Gozee, 6534, Belgium
  • SPRL Dr Yvan CALOZET
    Grigomont, 6887, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • SPRL MG Balthazar & Ballard
    Natoye, 5360, Belgium
  • Mortelmans, Jaak
    Oostham, 3945, Belgium
  • DCC 'Sv. Pantaleymon' OOD
    Pleven, 5800, Bulgaria
  • UMHAT "Kaspela", EOOD
    Plovdiv, 4002, Bulgaria
  • MHAT - Ruse, AD
    Ruse, 7002, Bulgaria
  • MHAT "Hadzhi Dimitar", OOD
    Sliven, 8800, Bulgaria
  • NMTH "Tsar Boris III"
    Sofia, 1233, Bulgaria
  • "City Clinic UMHAC" EOOD
    Sofia, 1407, Bulgaria
  • MHAT 'Tokuda Hospital Sofia', EAD
    Sofia, 1407, Bulgaria
  • UMHAT "Sv. Ivan Rilski", EAD
    Sofia, 1431, Bulgaria
  • UMHAT 'Tsaritsa Yoanna - ISUL', EAD
    Sofia, 1527, Bulgaria
  • Fourth MHAT - Sofia EAD
    Sofia, 1606, Bulgaria
  • UMHAT "SofiaMed", OOD
    Sofia, 1797, Bulgaria
  • Okresni nemocniceStrakonice
    Strakonice, 386 01, Czechia
  • OU Innomedica
    Tallinn, 10117, Estonia
  • Merekivi Perearstid OU
    Tallinn, 10617, Estonia
  • Merelahe Family Doctors Centre
    Tallinn, 10617, Estonia
  • West Tallinn Central Hospital
    Tallinn, 10617, Estonia
  • North Estonia Medical Centre Foundation
    Tallinn, 13419, Estonia
  • Tartu University Hospital
    Tartu, 51014, Estonia
  • SP ZOZ Wojewodzki Szpital Zespolony im. J. Sniadeckiego
    Bialystok, 15-275, Poland
  • NZOZ Inter-Med
    Czestochowa, 42-217, Poland
  • Centrum Medyczne Plejady
    Krakow, 30-349, Poland
  • Gabinet Endoskopii Przewodu Pokarmowego
    Krakow, 31-009, Poland
  • Centrum Medyczne Medyk
    Rzeszow, 35-055, Poland
  • Specjalistyczna Praktyka Lekarska Dr med. Marek Horynski
    Sopot, 81-756, Poland
  • SONOMED Sp.z o.o
    Szczecin, 71-685, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej Nasz Lekarz Praktyka Grupowa Lekarzy Rodzinnych z
    Torun, 87-100, Poland
  • Nzoz Vivamed
    Warszawa, 03-580, Poland
  • LexMedica Osrodek Badan Klinicznych
    Wroclaw, 53-114, Poland
  • EMC Instytut Medyczny S.A.
    Wroclaw, 54-144, Poland
  • Plympton Health Centre
    Plymouth, Devon PL7 1AD, United Kingdom
  • Whipps Cross University Hospital
    London, Greater London E11 1NR, United Kingdom
  • Sheepcot Medical Centre
    Watford, Hertfordshire WD25 0EA, United Kingdom
  • Royal Stoke University Hospital
    Stoke on Trent, Staffordshire ST4 6QG, United Kingdom
  • CPS Research
    Glasgow, Strathclyde G20 0XA, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Oct 2018, 26 months.

Results were first posted in Feb 2020, 1 year 4 months after primary completion.

Of 14 phase 2 interventional studies under Gastroesophageal Reflux, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's 26 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2016
First posted
Apr 19, 2016
StartActual
Jul 14, 2016
Primary completionActual
Oct 5, 2018
CompletionActual
Oct 12, 2018
Results first posted
Feb 18, 2020
Last update
Feb 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02743949
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Apr 19, 2016
Start date
Jul 14, 2016
Primary completion
Oct 5, 2018
Completion
Oct 12, 2018
Results posted
Feb 18, 2020
Last update
Feb 18, 2020

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esomeprazole

Start the discussion